Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, et al. N Engl J Med 2024;391:213-223.

Read + Share

Amedeo Smart

Independent Medical Education

Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. N Engl J Med 2024;391:213-223.
PMID: 39018531